I wouldn't get my hopes up for the future futility analysis new release to reveal too much other than the drug hopefully passing the safety and futility tests. I would expect something along the lines of the recent REVEAL/Anacetrapib interim analysis news release. However, if and when we get a similar announcement for RVX-208, this would help alleviate fears of safety and futility to a certain degree, which is still positive.

"Merck Provides Update on REVEAL Outcomes Study

Friday, November 13, 2015 8:00 am EST

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Data Monitoring Committee (DMC) of the REVEAL outcomes study for anacetrapib has completed its planned review of unblinded study data and recommended the study continue with no changes. The DMC reviewed safety and efficacy data from the study, which included an assessment of futility. Merck remains blinded to the actual results of this analysis and to other REVEAL safety and efficacy data.

REVEAL is a 30,000 patient, event-driven study sponsored by Oxford University, which is projected to conclude in early 2017. The REVEAL Steering Committee and Merck will continue to monitor the progress of the study. No additional interim efficacy analyses are planned."